¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"median tolerance limit"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • median aperture of fourth ventricle
    ³Ý°³ú½ÇÁ¤Áß±¸¸Û, Á¦4³ú½ÇÁ¤Áß°ø
  • median artery
    Á¤Áßµ¿¸Æ
  • median atlantoaxial articulation
    Á¤Áß°í¸®Áß¼è°üÀý, Á¤ÁßȯÃà°üÀý
  • median cleft lip
    Á¤ÁßÀÔ¼ú°¥¸²(Áõ), Á¤Áß±¸¼ø¿­
  • median cubital vein
    ÆÈ¿À±ÝÁß°£Á¤¸Æ, Á¤ÁßÁÖ¿ÍÁ¤¸Æ
  • median effective dose
    1. Áß°£À¯È¿¿ë·® 2. Áß°£À¯È¿¼±·®
  • median erythrocyte diameter
    Á¤ÁßÀûÇ÷±¸Áö¸§
  • median forehead flap
    Á¤ÁßÀ̸¶ÇÇÆÇ, Á¤ÁßÀüµÎºÎÇÇÆÇ
  • median groove of tongue
    ÇôÁ¤Áß°í¶û, ¼³Á¤Áß±¸
  • median lethal dose
    1. Áß°£Ä¡»ç¿ë·® 2. Áß°£Ä¡»ç¼±·®
  • median nail dystrophy
    Á¤Áß¼Õ¹ßÅéÀÌ»óÁõ
  • median nerve
    Á¤Á߽Űæ
  • median nucleus
    Á¤ÁßÇÙ
  • median plane
    Á¤Á߸é
  • median raphe
    Á¤Áß¼Ö±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • median lingual sulcus
    ÇôÁ¤Áß°í¶û
  • median sagittal plane
    (¢¡median plane) Á¤Á߸é
  • posterior median sulcus
    µÚÁ¤Áß°í¶û
  • acceleration tolerance
    °¡¼Ó³»¼º
  • acquired tolerance
    ȹµæÇã¿ë, ÈÄõ³»¼º, ÈÄõÇã¿ë, ȹµæ°ü¿ë
  • adoptive tolerance
    ÀÔ¾ç¸é¿ªÇã¿ë
  • cross-tolerance
    ±³Â÷³»¼º
  • carbohydrate tolerance test
    ź¼öÈ­¹°³»¼º½ÃÇè
  • cortisone glucose tolerance test
    ÄÚ¸£Æ¼¼ÕÆ÷µµ´çºÎÇϽÃÇè
  • cross tolerance
    ±³Â÷³»¼º
  • drug tolerance
    ¾à¹°³»¼º, ¾à¹°ÀúÇ×¼º
  • maximum tolerance dose
    ÃÖ´ë³»¾à¿ë·®, ÃÖ´ë³»¾à·®, ÃÖ´ë°ßµõ¼±·®
  • organ tolerance dose
    ±â°ü°ßµõ¼±·®
  • tolerance dose
    °ßµõ¼±·®
  • exercise tolerance test
    ¿îµ¿³»¼º°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • glucose tolerance test =GTT
    ´çºÎÇϰ˻ç(ÓØÝ¶ùÃËþÞÛ).
  • heat tolerance
    ³»¿­¼º(Ò±æðàõ).
  • heat tolerance
    ³»¿­¼º(ËÀËçËÛ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(¡­Ò±àõãËúÐ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(?ËÀËÛËàÌ´).
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º½ÃÇè.
  • high dose tolerance
    °ú·®°ü¿ë
  • high-zone tolerance
    °í¿ª°ü¿ë, Ç׿ø°ú·®°ü¿ë
  • immune tolerance
    ¸é¿ª°ü¿ë
  • immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
  • immunologic tolerance
    ¸é¿ª°ü¿ë(¡­Î°é»)
  • immunological tolerance
    ¸é¿ª³»¼º.
  • induction, tolerance
    °ü¿ëÀ¯¹ß (¸é¿ª)
  • infectious tolerance
    Àü´Þ¼º ¸é¿ª°ü¿ë
  • insulin tolerance
    Àν¶¸°³»¼º.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • alkali tolerance
    ¾ËÄ®¸®³»¼º(¡­Ò±àõ)
  • altimeter tolerance
    ³»°í¼Ò¼º(ËÀË­ËÛËÛ).
  • antigen tolerance
    Ç׿ø°ü¿ë.
  • autoimmune disease,immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
  • autoimmune disease,tolerance
    ³»¿ë·Â(Ò®é»æ³)
  • carbohydrate tolerance
    ź¼öÈ­¹°ºÎÇÏ(¡­Ý¶ùÃ), ź¼öÈ­¹°³»Àμº.
  • carbohydrate tolerance test
    ź¼öÈ­¹°ºÎÇϽÃÇè.
  • cortisone glucose tolerance test =CGTT
    ÄÚ¸£Æ¼¼Õ Æ÷µµ´ç ºÎÇϽÃÇè(¡­øã Ô¬ÓØÝ¶ùÃãËúÐ).
  • cross tolerance
    ±³Â÷³»¼º(Îßó©Ò±àõ)
  • cross tolerance
    ±³Â÷¸é¿ª°ü¿ë
  • cross-tolerance
    ±³Â÷³»¼º(Îßó©Ò±àõ)
  • diabetes mellitus,oral glucose tolerance test
    °æ±¸´çºÎÇÏ °Ë»ç(ÌèÏ¢ÓØÝ¶ùà ËþÞÛ)
  • drug disposition tolerance
    ¾à¹°ºÐÇØ³»¼º.
  • drug tolerance
    ¾à¹°<¾àÁ¦>³»¼º.
  • drug tolerance
    ¾à¹°³»¼º(å·ÚªÒ±àõ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Median nasal process
    Á¤ÁßÄÚµ¹±â
    [¿¾ ¿ë¾î] Á¤ÁߺñÀ¶±â
  • Median nuclei
    Á¤ÁßÇÙ
    [¿¾ ¿ë¾î] Á¤ÁßÇÙ
  • Median glosso-epiglottic fold
    Á¤ÁßÇôµ¤°³ÁÖ¸§
    [¿¾ ¿ë¾î] Á¤Áß¼³Èĵΰ³ÁÖ¸§
  • Median arcuate ligament
    Á¤ÁßȰ²ÃÀδë
    [¿¾ ¿ë¾î] Á¤Á߱ûóÀδë
  • Median cubital vein
    ÆÈ¿À±ÝÁß°£Á¤¸Æ
    [¿¾ ¿ë¾î] ÁÖÁ¤ÁßÇÇÁ¤¸Æ
  • Median lingual sulcus
    ÇôÁ¤Áß°í¶û
    [¿¾ ¿ë¾î] ¼³Á¤Áß±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TLV Threshold Limit Value
TLV-C Threshold Limit Value-Ceiling
  = MAC(Maximum Allowable Concentration)
  ...
TLV-STEL Threshold Limit Value-STEL; ´Ü½Ã°£ ÃÖ´ëÇã¿ë·®
  ; 15ºÐ°£ Æø·ÎµÇ¸é¼­ ÀÚ±ØÁõ»ó, Á¶Á÷¼Õ»óµîÀ» ÃÊ·¡ÇÏÁö ¾Ê´Â ÃÖ´ë ³óµµ, 1 ÀÏ¿¡ ...
TLV-TWA Threshold Limit Value-Time Weighted Average
  ; 1 ÀÏ 8 ½Ã°£ ÁÖ 40½Ã°£(¹Ì±¹), ÁÖ 48½Ã°£(Çѱ¹, ÀϺ»)À» ±â...
WNL Within Normal Limit(?)
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CI confidence limit
LOQ limit of quantification
LLOQ lower limit of quantitation
LLQ lower limit of quantitation
ULN upper limit of normal
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • poison tolerance
    µ¶¹° ³»¼º
    Áö¼ÓÀûÀÎ µ¶¼º ¹°Áú¿¡ ÀÇÇØ »ýü°¡ ±× µ¶¼º ¹°Áú¿¡ ÀúÇ×¼ºÀ» ³ªÅ¸³»´Â °Í.
  • tolerance
    ³»¾à¼º, ³»¼º, ³»¿ë·Â, Çã¿ë, °ü¿ë
    1. º¸Åë ¾à¹°À̳ª µ¶¹°ÀÇ ¸¹Àº »ç¿ë·®À» °ßµð¾î ³¾ ¼ö ÀÖ´Â ´É·Â. 2. ÈÄõÀûÀ¸·Î ȹµæµÈ ¾à¹° ³»¼º. ¹Ýº¹ÀûÀÎ µ¿·®ÀÇ »ç¿ë·®¿¡ ´ëÇÑ ¹ÝÀÀ¼ºÀÇ °¨¼Ò ȤÀº °°Àº ¹ÝÀÀÀ» ¾ò±â À§Çؼ­ Áõ°¡µÈ »ç¿ë·®À» ¿ä±¸ÇÏ´Â °Í.
  • tolerance span
    Àγ» ±â°£
  • tolerance to antimicrobial
    Ç×±ÕÁ¦ ³»¼º
  • tolerance to high altitude
    °í¼Ò ³»¼º
  • dorsal median septum
    µÚ Á¤Áß »çÀÌ ¸·
  • median
    Á¤ÁßÀÇ, Áß¾ÓÀÇ, Áß¾Ó°ª
  • median antebrachial vein
    ¾Æ·¡ ÆÈ Áß°£ Á¤¸Æ
  • median artery
    Á¤Áß µ¿¸Æ, Á¤Áß ½Å°æ ¹ÝÇà µ¿¸Æ, Á¤Áß ½Å°æ µ¿¹Ý µ¿¸Æ
    Àü°ñ°£ µ¿¸Æ¿¡¼­ ±â¿øÇϸç, Á¤Á߽Űæ, Àü¿Ï ¾ÕÂÊÀÇ ±ÙÀ°¿¡ ºÐÆ÷ÇÑ´Ù.
  • median bar
    Áß»è, Á¤Á߸ª
    Àü¸³¼±ÀÇ °æºÎ¸¦ °¡·ÎÁö¸£´Â ¼¶À¯¼º Áõ½ÄÀ¸·Î ¿äµµ Æó»öÀÇ ¿øÀÎÀÌ µÈ´Ù.
  • median cubital vein
    ÆÈ¿À±Ý Áß°£ Á¤¸Æ, ÁÖÁßÁ¤ÇÇ Á¤¸Æ
    ÆÈ²ÞÄ¡ ÇϹæÀÇ ¿äÃø ÇÇÁ¤¸Æ¿¡¼­ ±â½ÃÇÏ´Â Å« ¿¬¶ôÁö. ºñ½ºµëÈ÷ Áֿ͸¦ ³Ñ¾î »óÃøÀ¸·Î ÁÖÇàÇϸç ̫̿ ÇÇÁ¤¸Æ°ú ¸¸³­´Ù.
  • median diastema
    Á¤Áß À̰³
  • median fissure
    Áß¾Ó ¿­±¸
  • median groove of tongue
    ¼³ Á¤Áß±¸
  • median jaw relation
    Á¤Áß ¾Ç°ü °ü°è
    ÇϾÇÀÌ Á¤Áß ½Ã»ó Æò¸é¿¡ À§Ä¡ÇÒ ¶§ÀÇ ¸ðµç ¾Ç°£ °ü°è.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
high dose tolerance The induction of tolerance by exposure to high doses of antigen.
(05 Mar 2000)
xylose tolerance test <investigation> This test measures the intestine's ability to absorb the simple sugar, D-xylose.
This is an indicator for whether or not nutrients are being absorbed properly in the intestine. This test is often used to evaluate persistent diarrhoea, weight loss, malnutrition and cases of suspected malabsorption.
Abnormal results may be seen in the following conditions: Crohn's disease, Giardiasis, hookworm infestation, radiation enteritis, celiac sprue, viral gastroenteritis and Whipple's disease.
(27 Sep 1997)
self tolerance The normal lack of the ability to produce an immunological response to autologous (self) antigens. A breakdown of self tolerance leads to autoimmune diseases. The ability to recognise the difference between self and non-self is the prime function of the immune system.
(12 Dec 1998)
species tolerance The insensitivity to a particular drug exhibited by a particular species.
(05 Mar 2000)
split tolerance Modification of an immune response to an antigen after prior exposure to that antigen.
Synonym: split tolerance.
(05 Mar 2000)
nonresponder tolerance Lack of immune response to antigen. Theories of tolerance induction include clonal deletion and clonal anergy. In clonal deletion, the actual clone of cells is eliminated whereas in clonal anergy the cells are present but nonfunctional.
Synonym: immunological tolerance, immunotolerance, nonresponder tolerance.
(05 Mar 2000)
drug tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from drug resistance wherein a human, animal, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug.
(12 Dec 1998)
immune tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (foetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
(12 Dec 1998)
immunological tolerance <immunology> Specific unresponsiveness to antigen. Self tolerance is a process occurring normally early in life due to suppression of self reactive lymphocyte clones.
Tolerance to foreign antigens can be induced in adult life by exposure to antigens under conditions in which specific clones are suppressed. Note that tolerance is not the same as immunological unresponsiveness, since the latter may be very non-specific as in immunodeficiency states.
(18 Nov 1997)
immunologic high dose tolerance Induction of tolerance by exposure to large amounts of protein antigens.
(05 Mar 2000)
immunologic tolerance Lack of immune response to antigen. Theories of tolerance induction include clonal deletion and clonal anergy. In clonal deletion, the actual clone of cells is eliminated whereas in clonal anergy the cells are present but nonfunctional.
Synonym: immunological tolerance, immunotolerance, nonresponder tolerance.
(05 Mar 2000)
impaired glucose tolerance Blood glucose (sugar) levels higher than normal but not high enough to be called diabetes. People with impaired glucose tolerance may or may not develop diabetes.
Other names (no longer used) for impaired glucose tolerance are borderline, subclinical, chemical, or latent diabetes.
(30 Mar 1998)
individual tolerance Tolerance to a drug that the person has never received before.
(05 Mar 2000)
oral lactose tolerance test A test for lactose deficiency; the plasma glucose response to an oral lactose load is measured as in the (oral) glucose tolerance test.
(05 Mar 2000)
test, glucose tolerance After fasting, a specific amount (100 grams) of glucose is given by mouth, and the blood levels of this sugar are measured every hour. Normally, the blood glucose should return to normal within 2 to 2 1/2 hours. The gtt is considered a classic test of carbohydrate metabolism. It is much used in the diagnosis of diabetes. The gtt depends on a number of factors including the ability of the intestine to absorb glucose, the power of the liver to take up and store glucose, the capacity of the pancreas to produce insulin, and the amount of active insulin.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á